<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731286</url>
  </required_header>
  <id_info>
    <org_study_id>EB/180401/ENXTRA/EVRG</org_study_id>
    <nct_id>NCT03731286</nct_id>
  </id_info>
  <brief_title>A Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults</brief_title>
  <official_title>A Double-Blind Randomized, Double-dummy, Placebo-controlled, Parallel-Group Study of the Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study has been proposed to investigate the long-term safety and efficacy of&#xD;
      EnXtra in healthy adults habituated to caffeine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2018</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ECG from baseline to end of the treatment.</measure>
    <time_frame>84 Days</time_frame>
    <description>ECG parameters including PR interval, QRS duration, QT interval and RR interval will be evaluated from baseline and end of the treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Caffeine Dependence</condition>
  <arm_group>
    <arm_group_label>Alpinia galanga</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EnXtra: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Composite (Alpinia galanga + Caffeine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Composite: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpinia Galanga</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>Alpinia galanga</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpinia Galanga</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>Composite (Alpinia galanga + Caffeine)</arm_group_label>
    <other_name>Caffeine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Microcellulose crystalline</intervention_name>
    <description>2 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of regular caffeine consumption.&#xD;
&#xD;
          2. Body mass index (BMI) of ≥18.5 and &lt;25.00 kg/m2.&#xD;
&#xD;
          3. Fasting blood glucose &lt; 126 mg/dl&#xD;
&#xD;
          4. Participants who are willing to complete all study procedures including study-related&#xD;
             questionnaires and comply with study requirements.&#xD;
&#xD;
          5. Participants who are willing to abstain from use of any nutritional supplement and&#xD;
             herbal preparation 48 hrs prior to study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants unable to abstain from caffeine-containing products for 12 hours prior to&#xD;
             the site visit.&#xD;
&#xD;
          2. Known cases of type II Diabetes Mellitus.&#xD;
&#xD;
          3. Participants with uncontrolled hypertension (≥140/90 mm Hg), with or without&#xD;
             anti-hypertensive medication.&#xD;
&#xD;
          4. Participants suffering from primary or secondary insomnia with/ without active&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vedic Lifesciences Pvt. Ltd</name>
      <address>
        <city>Mumbai</city>
        <state>Opp Infinity Mall</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

